These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10545714)

  • 21. Role of opioid ligands in the irritable bowel syndrome.
    Corazziari E
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():71A-75A. PubMed ID: 10202212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel medications for the irritable bowel syndrome: motility and sensation.
    Camilleri M
    J Pediatr Gastroenterol Nutr; 2001; 32 Suppl 1():S35-7. PubMed ID: 11321419
    [No Abstract]   [Full Text] [Related]  

  • 23. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
    Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Irritable bowel syndrome: diagnostic criteria and recent advancement of its pharmacological management].
    Matsueda K
    Nihon Shokakibyo Gakkai Zasshi; 2001 Oct; 98(10):1146-53. PubMed ID: 11680988
    [No Abstract]   [Full Text] [Related]  

  • 27. Visceral hypersensitivity in irritable bowel syndrome.
    Kanazawa M; Hongo M; Fukudo S
    J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():119-21. PubMed ID: 21443723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotoninergic neuroenteric modulators.
    Talley NJ
    Lancet; 2001 Dec; 358(9298):2061-8. PubMed ID: 11755632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irritable bowel syndrome and visceral hypersensitivity : risk factors and pathophysiological mechanisms.
    Deiteren A; de Wit A; van der Linden L; De Man JG; Pelckmans PA; De Winter BY
    Acta Gastroenterol Belg; 2016 Mar; 79(1):29-38. PubMed ID: 26852761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging pharmacological therapies for the irritable bowel syndrome.
    Maneerattanaporn M; Chang L; Chey WD
    Gastroenterol Clin North Am; 2011 Mar; 40(1):223-43. PubMed ID: 21333909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychotherapeutics and serotonin agonists and antagonists.
    Mertz H
    J Clin Gastroenterol; 2005; 39(5 Suppl 3):S247-50. PubMed ID: 15798492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The challenge of irritable bowel syndrome: creating an alliance between patient and physician.
    Shen B; Soffer E
    Cleve Clin J Med; 2001 Mar; 68(3):224-5, 229-33, 236-7. PubMed ID: 11263850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-Hydroxytryptamine and functional bowel disorders.
    Sanger GJ
    Neurogastroenterol Motil; 1996 Dec; 8(4):319-31. PubMed ID: 8959736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tachykinin receptor antagonists in irritable bowel syndrome.
    Lecci A; Valenti C; Maggi CA
    Curr Opin Investig Drugs; 2002 Apr; 3(4):589-601. PubMed ID: 12090730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dimensions of gut dysfunction in irritable bowel syndrome: altered sensory function.
    Azpiroz F
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():12A-14A. PubMed ID: 10202202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug treatment of the irritable bowel syndrome.
    Pattee PL; Thompson WG
    Drugs; 1992 Aug; 44(2):200-6. PubMed ID: 1382014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel diagnostics and therapy of colonic motor disorders.
    Dinning PG; Scott SM
    Curr Opin Pharmacol; 2011 Dec; 11(6):624-9. PubMed ID: 22019567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin and neuroprotection in functional bowel disorders.
    Gershon MD; Liu MT
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2(Suppl 2):19-24. PubMed ID: 17620084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders.
    Mearin F
    Digestion; 2006; 73 Suppl 1():28-37. PubMed ID: 16498250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M; Pace F
    Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.